All news
IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders
Dr. Richard L. Abbott and Dr. Lixin Xie join IACTA's Scientific Advisory Board Guaynabo, Puerto Rico, June 29, 2022 — IACTA Pharmaceuticals, Inc. ("IACTA"), an innovation leader in
IACTA Pharmaceuticals to Present at Jefferies Healthcare Conference
Damon Burrows, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:30 a.m. ET. Guaynabo, Puerto Rico, June 1, 2022 —
IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology
Strategic collaboration and licensing agreement to allow for co-development leveraging IACTA formulation and clinical expertise and TALLC’s SmartCelle™ delivery technology Collaboration to expand IACTA’s diverse ophthalmology pipeline Guaynabo,
CEO Damon Burrows featured on OIS Podcast
From Big Pharma Lawyer to Eye Care Disruptor: IACTA Pharmaceuticals Founder & CEO Damon Burrows OIS Podcast host Rob Rothman, MD, caught up with Damon to discuss his
IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury
U.S. Department of Defense has granted a $1 million award to IACTA to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain
IACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer
Expanded executive team focused on developing IACTA’s novel pipeline of ophthalmic drugs including a dual enkephalinase inhibitor for ocular pain, and SYK kinase inhibitor for dry eye disease
IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
Ocular Pain, a $10+ billion global market, with significant unmet medical need License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies IRVINE, Calif.,
IACTA Pharmaceuticals featured in Orange County Business Journal’s Startups and Innovations section
By Jessie Yount - Featured on ocbj.com CLINICAL TRIALS IACTA Pharmaceuticals Inc. in Irvine nabbed a licensing agreement with Zhaoke Ophthamology Pharmaceutical to co-develop and commercialize two drug candidates in
IACTA Pharmaceuticals and Zhaoke Ophthalmology agree to co-develop novel eye treatments
By David Ho and Elise Mak - Featured on BioWorld.com HONG KONG - California-based Iacta Pharmaceuticals Inc. and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical Ltd. have inked a definitive license agreement
New licensing agreement accelerates the development of IACTA Pharmaceuticals’ novel dry eye disease and allergic conjunctivitis treatments on China and Southeast Asia
IRVINE, Calif. and HONG KONG -- IACTA Pharmaceuticals, Inc. ("IACTA" or the "Company") and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited ("ZKO"), a leading Hong Kong-based pharmaceutical company, today announces they
Update on the in-licensing and research and development of ophthalmology products
This announcement is made by the board of directors (the “Board”) of Lee’s Pharmaceutical Holdings Limited (the “Company”, together with its subsidiaries as the “Group”) on a voluntary basis. The
Connect with us